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Bone remodeling is a continuous process to retain the structural integrity and function 
of the skeleton. A tight coupling is maintained between osteoclast-mediated resorption 
of old or damaged bones and osteoblast-mediated formation of new bones for bone 
homeostasis. While osteoblasts differentiate from mesenchymal stem cells, osteoclasts 
are hematopoietic in origin and derived from myeloid precursor cells. Osteoclast differen-
tiation is driven by two cytokines, cytokine receptor activator of NF-κB ligand (RANKL), 
and macrophage colony-stimulating factor. Imbalances in the activity of osteoblasts 
and osteoclasts result in the development of bone disorders. Bacterially caused porcine 
atrophic rhinitis is characterized by a loss of nasal ventral conche bones and a distortion 
of the snout. While Bordetella bronchiseptica strains cause mild and reversible symp-
toms, infection of pigs with toxigenic Pasteurella multocida strains causes a severe and 
irreversible decay. The responsible virulence factor Pasteurella multocida toxin (PMT) 
contains a deamidase activity in its catalytical domain that constitutively activates specific 
heterotrimeric G proteins to induce downstream signaling cascades. While osteoblasts 
are inhibited by the toxin, osteoclasts are activated, thus skewing bone remodeling 
toward excessive bone degradation. Still, the mechanism by which PMT interferes with 
bone homeostasis, and the reason for this unusual target tissue is not yet well under-
stood. Here, we show that PMT has the potential to differentiate bone marrow-derived 
macrophages into functional osteoclasts. This toxin-mediated differentiation process is 
independent of RANKL, a cytokine believed to be indispensable for triggering osteoclas-
togenesis, as addition of osteoprotegerin to PMT-treated macrophages does not show 
any effect on PMT-induced osteoclast formation. Although RANKL is not a prerequisite, 
toxin-primed macrophages show enhanced responsiveness to low concentrations of 
RANKL, suggesting that the PMT-generated microenvironment offers conditions where 
low concentrations of RANKL lead to an increase in the number of osteoclasts resulting 
in increased resorption. PMT-mediated release of the osteoclastogenic cytokines such as 
IL-6 and TNF-α, but not IL-1, supports the differentiation process. Although the produc-
tion of cytokines and the subsequent activation of signaling cascades are necessary for 
PMT-mediated differentiation into osteoclasts, they are not sufficient and PMT-induced 
activation of G protein signaling is essential for efficient osteoclastogenesis.
Keywords: bacterial toxin, osteoclast, immune evasion, pro-inflammatory cytokines, g protein, Pasteurella 
multocida toxin
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inTrODUcTiOn
Bone is a dynamic tissue, which is constantly remodeled to 
regulate its structural integrity and functions. Bone remodeling 
is a physiological process to maintain homeostasis and involves 
the removal of old or damaged bone structures by osteoclasts and 
the subsequent replacement of new bone by osteoblasts. A tight 
coupling of bone resorption to bone formation is maintained 
in normal bone homeostasis. However, bacterial infections 
can derail this process and result in bone diseases like caries, 
periodontitis, osteomyelitis, septic arthritis, lyme disease, and 
atrophic rhinitis (AR) (1). Bacteria can mediate bone damage 
by (a) releasing substances, which can directly destroy the bone 
matrix, (b) by activating osteoclasts or inhibiting osteoblasts 
through their surface or secreted components, (c) by stimulat-
ing inflammatory cells, which subsequently activate osteoclasts 
resulting in enhanced bone resorption, and (d) by invading 
osteoblasts resulting in inhibition of bone matrix formation and 
dysregulation of bone remodeling (2).
One of the most potent bacterial toxin involved in bone 
destruction is Pasteurella multocida toxin (PMT), which is pro-
duced by capsular type D or some type A strains of Pasteurella 
multocida (3). PMT is the causative agent of porcine AR, an 
economically important disease, characterized by degeneration 
of nasal turbinate bones, leading to a shortening or twisting of 
the snout (4). In humans, few and rare cases of septic arthritis 
have been reported due to P. multocida infection, and these are 
usually caused by animal bites (5, 6). PMT is a 146 kDa protein 
and acts as a potent mitogen for cell types such as osteoclasts 
or fibroblasts (7, 8). In piglets, administration of purified PMT 
on nasal conche is sufficient to cause AR (9). The toxin medi-
ates AR through interfering with bone biogenesis by promoting 
osteoclast differentiation and proliferation resulting in increased 
bone resorption, while inhibiting osteoblast differentiation and 
bone regeneration on the other hand (10–14). The mode of action 
of PMT on host cells is through activation of heterotrimeric G 
protein families Gαq/11, Gαi1–3, and Gα12/13 but not through Gαs 
activation (15). PMT induces the permanent activation of het-
erotrimeric G proteins of the host by deamidation of a conserved 
glutamine residue in the switch II region of the α subunit, critical 
to maintain the intrinsic GTPase activity of G protein (16). As a 
consequence of constitutive activation of host G proteins by PMT, 
signaling cascades such Map kinase, JAK-STAT, or PI3 kinase 
pathway are activated, which result in mitogenesis, increased 
survival, and cytoskeletal reorganization (17). We hypothesize 
that bone destruction is a side-effect of toxin-induced produc-
tion of cytokines in an attempt to modulate signal transduction 
pathways of innate and adaptive immune cells to avoid immune 
recognition (18).
Osteoclasts differentiate from hematopoietic precursors of 
the monocyte/macrophage lineage through the action of two 
cytokines, RANKL and macrophage colony-stimulating factor 
(M-CSF). Upon stimulation of their cognate receptors, a cas-
cade of signaling events is initiated leading to the activation of 
transcription factors such as nuclear factor of activated T cells, 
calcineurin dependent 1 (NFATc1), NF-kB, and AP-1, result-
ing in the fusion of precursor cells and expression of genes for 
osteoclast functions (19). Mice deficient in the cytokines M-CSF 
and RANKL or their cognate receptors display a prominent 
osteopetrotic phenotype. Osteoprotegerin (OPG) is a soluble 
receptor that competes with RANK for RANKL and protects 
the skeleton from excessive bone resorption. Overexpression or 
administration of OPG in mice results in profound osteopetrosis 
by reducing osteoclastogenesis (20). Under physiological condi-
tions the RANKL/OPG ratio is balanced to maintain skeletal 
integrity.
Osteoclastogenic plasticity has been observed across the 
myeloid lineage ranging from early myeloid precursors to mono-
cytes, macrophages, and dendritic cells, which can differentiate 
into tartrate-resistant acid phosphatase (TRAP)-positive osteo-
clasts in the presence of soluble RANKL (sRANKL) and M-CSF 
(21–23). Studies from our group and others have shown the 
osteoclastogenic property of PMT in cell lines or heterogeneous 
precursor populations (24–26); therefore, we decided to inves-
tigate the potential of PMT in inducing osteoclastogenesis in a 
homogeneous population of bone marrow-derived macrophages 
(BMDMs) to unravel the mechanism of osteoclast differentiation 
in more detail. We show that PMT drives the differentiation of 
BMDMs into TRAP-positive cells independent of RANKL-RANK 
signaling, as treatment of PMT-stimulated BMDMs with OPG 
did not abrogate osteoclast formation. In addition, our investiga-
tion shows that PMT-induced osteoclastogenesis is modulated 
by cytokines and their downstream signaling pathways that are 
necessary but not sufficient for efficient differentiation of mac-
rophages into osteoclasts.
MaTerials anD MeThODs
ethics statement
All animal studies were approved by the Regierungspräsidium 
Karlsruhe, Germany.
Mice
C57BL/6 wild-type mice were purchased from Janvier Labs (Le 
Genest St. Isle, France), and IL-1R-deficient mice were obtained 
from Jackson Laboratories (Bar Harbor, ME, USA). Mice were 
maintained under SPF conditions in accordance with the German 
policies on animal welfare.
reagents
Tissue culture reagents were purchased from Biochrom GmbH 
(Berlin, Germany), PAA laboratories, PAN biotech (Aidenbach, 
Germany), Merck and Sigma, respectively. Antibodies against 
phosphorylated c-Jun (p-c-Jun) (Ser63), p-NF-kB (Ser536), 
phosphorylated STAT-3 (Tyr705), HistonH3, and β-actin were 
purchased from Cell Signaling Technology (Frankfurt, Germany). 
Antibodies against NFATc1 and Gq were procured from Santa 
Cruz Biotechnology (Heidelberg, Germany). An antibody that 
recognizes the Q209E modification of Gαq was a gift of Prof. 
S. Kamitami (Osaka, Japan). Secondary HRP-linked antibodies 
were obtained from Cell Signaling Technology (anti-rabbit IgG, 
anti-Mouse IgG) or Santa Cruz (anti-rat IgG). FITC-conjugated 
anti-CD11b, FITC-conjugated anti-CD80, FITC-conjugated 
Table 1 | Primer sequences.
gene Forward reverse
Acp5 5′-TTC CAG GAG ACC TTT 
GAG GA-3′
5′-GGT AGT AAG GGC TGG GGA 
AG-3′
Oscar 5′-AGG GAA ACC TCA 
TCC GTT TG-3′
5′-GAG CCG GAA ATA AGG CAC 
AG-3′
Ctsk 5′-AGG GAA GCA AGC 
ACT GGA TA-3′
5′-GCT GGC TGG AAT CAC ATC 
TT-3′
Nfatc1 5′-GGG TCA GTG TGA 
CCG AGG AT-3′
5′-GGA AGT CAG AAG TGG GTG 
GA-3′
Ocstamp 5′-TGG GCC TCC ATA TGA 
CCT CGA GTA G-3′
5′-TCA AAG GCT TGT AAA TTG GAG 
GAG T-3′
Atp6v0d2 5′-TCA GAT CTC TTC AAG 
GCT GTG CTG-3′
5′-GTG CCA AAT GAG TTC AGA GTG 
ATG-3′
Rps29 5′-AGC CGA CTC GTT 
CCT TTC TC-3′
5′-CGT ATT TGC GGA TCA GAC C-3′
Tnf 5′-AGC CCC CAG TCT 
GTA TCC TT-3′
5′-CTC CCT TTG CAG AAC TCA 
GG-3′
Il6 5′-CCG GAG AG GAGA 
CTT CAC AG-3′
5′-TTC TGC AAG TGC ATC ATC 
GT-3′
Il1b 5′-ACT CAT TGT GGC TGT 
GGA GAA G-3′
5′-GCC GTC TTT CAT TAC ACA 
GGA-3′
Il1a 5′-CGG GTG ACA GTA 
TCA GCA AC-3′
5′-GAC AAA CTT CTG CCT GAC 
GA-3′
calcr 5′-AGA GTG AAA AGG 
CGG AAT CT-3′
5′-TTT GTA CTG AGC ATC CAG 
CA-3′
Tnfrsf11a 5′-CGA GGA AGA TTC 
CCA CAG AG-3′
5′-CAG TGA AGT CAC AGC CCT 
CA-3′
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anti-CD40 were from BD Biosciences (Heidelberg, Germany). 
PE-conjugated anti-CD86 and PECy7-conjugated anti-MHCII 
were purchased from eBioscience (Frankfurt, Germany). PECy7-
conjugated anti-F4/80 and PE-conjugated anti-RANK and the 
corresponding isotype control were purchased from BioLegend 
(San Diego, CA, USA).
Rat anti-mouse Interleukin 6 receptor (IL-6R) antibody was 
a gift from Chugai Pharmaceutical, Tokyo, Japan. Etanercept 
(Enbrel; Pfizer) used in blocking experiment of TNF-α was 
generously provided by Prof. G. Schett (Erlangen, Germany) and 
Prof. H. Lorenz (Heidelberg, Germany). The Anti-IL-6 antibody 
for blocking IL-6 signaling was obtained from BioXCell (West 
Lebanon, USA).
PCR primers were purchased from Apara (Denzlingen, 
Germany) or Biomol (Hamburg, Germany). Recombinant PMT 
and the catalytically inactive mutant PMTC1165S were kindly pro-
vided by Prof. Klaus Aktories (Freiburg).
Differentiation of bMDMs
Bone marrow (BM) cells were isolated from the femur and tibia 
of 6–12  weeks old C57BL/6 mice. These cells were then used 
to generate BMDMs, using L929-cell conditioned medium 
(LCCM) as a source of granulocyte/M-CSF. On day 1, BM 
cells were resuspended in 20 ml of complete medium (DMEM 
supplemented with 10% FBS, 100  U/ml penicillin, 100  µg/ml 
streptomycin, and 50 µM 2-mercaptoethanol). On day 2, non-
adherent cells were collected by flushing the petri dish several 
times. These cells were then resuspended in complete medium 
containing 30% LCCM. On day 4, 30% LCCM was again added 
and incubated for an additional 3 days. To obtain the BMDM, 
the supernatants were discarded and the attached cells were 
collected in 10 ml of complete medium and centrifuged at 200 g 
for 5 min.
stimulation
Cells were stimulated with 1  nM PMT or 20–100  ng/ml rec. 
mouse sRANKL, 25 ng/ml rec. mouse M-CSF 100 ng/ml OPG (all 
from R&D Systems, Abington, UK). For cytokine experiments, 
cells were treated with 700 pg/ml TNF-α (eBioscience), 2,500 pg/
ml IL-6, and 900 pg/ml IL-1β, respectively (Miltenyi, Bergisch-
Gladbach, Germany).
Quantitative real-time Pcr
A total of 1 × 106 BMDM cells were seeded per well in a 6-well plate 
and then stimulated as indicated. RNA was extracted using High-
Pure RNA isolation kit (Roche), according to the manufacturers’ 
protocol. cDNA was prepared by using Revert Aid First strand 
cDNA synthesis kit (Thermo Scientific). Quantitative RT-PCR was 
performed using SYBR Green Rox mix (Thermo Scientific) with 
the primers listed in Table 1. RT-PCR was performed using the 
7900 HT Fast Real-Time PCR System (AB Applied Biosystems). 
An initial denaturation step of 10 min at 95°C was common for all 
genes, but the following cycle for annealing and amplification was 
different. For Nfatc1, Il1a, Acp5, Ocstamp (40 cycles at 95°C for 
15 s and at 58°C for 1 min); calcr (50 cycles at 95°C for 10 s and at 
58°C for 45 s); Tnf, Il6, and Il1b (40 cycles at 95°C for 15 s and at 
60°C for 1 min); Ctsk, Atp6vod2, Oscar (40 cycles at 95°C for 15 s, 
60°C for 30 s, and 72°C for 30 s). As normalization control Rsp29 
was used, relative expression (rE) was calculated as rE = 1/(2ΔCt).
elisa
Supernatants of stimulated cells were harvested and analyzed for 
IL-6 and TNF-α using mouse IL-6 ELISA MAXTM Standard Set 
and mouse TNF-α ELISA MAXTM Standard Set, respectively 
(BioLegend, San Diego, CA, USA). A TecanGENios Pro plate 
reader (Tecan, Crailsheim, Deutschland) was used for quantifica-
tion. Results were analyzed using the Magellan5 software.
Determination of bone resorption  
Pit area
A total of 2.5 × 105 cells were plated in 1 ml of complete medium 
in 24-well plates and treated as mentioned. On day 3, cells were 
transferred to a 96-well plate containing bovine cortical bone 
slices (http://Boneslices.com, Jelling, Denmark) and cultivated 
for 15–21 days. For measurement of resorbed bone, bone slices 
were washed with phosphate buffer saline (PBS), incubated in 5% 
sodium hypochlorite for 1–2 h, washed thoroughly with water, 
and stained with 0.1% toluidine blue. The pits developed a blue to 
purple color. The resorbed area was calculated from micro images 
with Adobe® Photoshop® CS5.
TraP staining
A total of 2.5 × 105 cells were plated in 1 ml of complete medium 
in 24-well plates and treated as described in figure legends. Cells 
were then fixed and stained using Acid Phosphatase, Leukocyte 
(TRAP) Kit (Sigma, St. Louis, MO, USA). TRAP-positive cells 
with three or more nuclei were scored as osteoclasts.
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Western blot analysis
A total of 1 × 106 cells were stimulated in 2 ml of complete medium 
in a 6-well format as indicated with PMT. For the lysis, cells were 
washed twice with ice-cold PBS and collected in ice-cold PBS by 
scrapping. Cell pellets were lysed in 200 µl of 1× NP40 buffer, 
freshly supplemented with a Phosphatase and Protease-Inhibitor 
Cocktail (Roche). Lysates were separated by SDS-PAGE (4–20% 
gradient polyacrylamid gel, Anamed). Proteins were transferred 
to nitrocellulose membrane via semi-dry western blot, blocked 
in TBST (5% BSA) for 1  h at RT before the membranes were 
incubated with the primary antibody, diluted as suggested by 
Cell Signaling Technology over night at 4°C. After 1 h incubation 
with the secondary antibody (HRP-coupled), protein bands were 
detected by enhanced chemiluminescence.
nuclear extract Preparation
A total of 1.2 × 107 BMDMs were stimulated as indicated in the 
figure legend in 10 ml of complete medium. Nuclear extracts were 
prepared using a nuclear extraction kit (Active Motif). Briefly 
cells were washed and then collected by scrapping in ice-cold PBS 
containing phosphatase inhibitor. Cells were then centrifuged at 
500 g for 10 min at 4°C. Pellet was resuspended in 500 µl of 1× 
hypotonic buffer and incubated for 15 min on ice. Then 25 µl of 
detergent was added and vortexed for 10 s. Cells were then cen-
trifuged at 14,000 g for 1 min at 4°C. Supernatant containing the 
cytoplasmic fraction was transferred into new microcentrifuge 
tubes. The pellet was washed with PBS twice, resuspended in 50 µl 
of complete lysis buffer, vortexed, and incubated for 30 min rock-
ing on ice. After that the samples were centrifuged at 14,000 g for 
10 min, and the supernatant containing the nuclear fraction was 
collected. Western Blot analysis was performed with the nuclear 
fraction.
cathepsin K activity assay
A total of 5 ×  105 BMDMs were seeded per well in a six-well 
plate. Cells were then stimulated with either PMT or M-CSF or 
M-CSF+sRANKL for 6  days, and cathepsin K Activity Assay 
was performed (Abcam). Cells were lysed in 200 µl of cathepsin 
K cell lysis buffer and incubated on ice for 10 min. Cell debris 
were centrifuged at 14,000 g for 5 min, and the supernatants were 
removed. The amount of protein in the lysates was determined 
with a BCA Assay (Pierce), and the amount was adjusted to 3 µg 
of protein in 50 µl of lysis buffer per well of a 96-well plate. Fifty 
microliters of cathepsin K reaction buffer was added to each well. 
The Ac-LR-AFC substrate was added to a final concentration of 
140 µM, and the plate was incubated for 2 h at 37°C. Fluorescence 
was measured with a microplate reader (FLUOstar OPTIMA; 
BMG LABTECH) with an excitation of 355 nm and an emission 
of 520 nm.
Facs analysis
For FACS analysis 1 × 106 cells were used per sample. Cells were 
blocked for 15 min in PBS, 2% BSA on ice in a total volume of 
100 µl before staining the cells for 1 h on ice with the appropri-
ate antibody or incubated in the corresponding isotype control 
diluted as suggested by manufacturers. Surface expression of 
RANK (R12-31), CD11b (M1/70), CD80 (16-10A1), CD86 
(GL-1), F4/80 (BM8), CD40 (3/23), and MHCII (M5/114.15.2) 
was quantified by flow cytometry on a FACSCanto cytometer (BD 
Biosciences, Heidelberg, Germany). For RANK expression, the 
mean fluorescence intensity was recorded and the values were 
corrected for differences in basal fluorescence of unstained cells. 
Overlays were generated using Flowing Software 2.5.
Phagocytosis assay
5 × 105 cells were incubated in 100 µl of complete medium at 37°C 
or at 4°C with green fluorescent latex beads (diameter: 1  µm) 
diluted 1:100 for 1 h. Afterward, cells were washed five times with 
ice-cold PBS, and phagocytosis was measured by performing flow 
cytometry (FACSCanto cytometer, BD Biosciences, Heidelberg, 
Germany).
cytokine and inhibitor experiments
A total of 2.5 × 105 cells were plated in 1 ml of complete medium 
in 24-well plates and stimulated according as detailed in the 
figure legends. For the analysis of cytokine-mediated effects, 
cytokines were added to the appropriate stimuli or were added 
alone as cytokine mix directly afterward. Half of the medium 
was changed after 1½  days cytokines were replenished. After 
10–12 days, TRAP staining was performed. To address the role of 
IL-1, TNF-α and IL-6 signaling in PMT-induced osteoclastogen-
esis, BMDMs were generated from wt-mice and IL1-R-deficient 
mice and were treated with the inhibitor etanercept (Enbrel; 
Pfizer) with a concentration of 120 µg/ml and a neutralization 
antibody for murine IL-6 (anti m IL-6, BioXCell) at 105 µg/ml 
for 1 h prior to stimulation. Cells were stimulated with PMT and 
M-CSF, and the inhibitors were again added 12 h after stimula-
tion. Forty-eight hours after addition of the inhibitors, half of the 
medium was changed and stimulated or inhibited, respectively. 
After 10–12 days, a TRAP stain was performed.
statistical analyses
Data are presented as means ±  SD. Comparison between the 
groups was performed by employing a Student’s t-test. p values 
≤0.05 were considered statistically significant. Multiple-group 
comparisons were analyzed by analysis of variance.
resUlTs
PMT Triggers Osteoclast Formation in 
Mouse bMDMs
Pasteurella multocida toxin was shown to have the potential to 
differentiate osteoclast precursors into osteoclasts in pig, mouse, 
and rat models using heterogeneous and mostly ill-defined 
precursor populations (11, 25, 27). As none of these studies 
checked the osteoclastogenic potential of PMT on a homogenous 
population of macrophages devoid of stromal or osteoblastic 
contamination, we decided to investigate the effect of PMT in 
BMDMs as a model system. After an initial characterization of 
the population for the expression of typical macrophage markers 
that allow to distinguish macrophages from monocytes (Figure 
S1 in Supplementary Material) (28), macrophages were washed 
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and stimulated with PMT, in the absence of M-CSF or other 
cytokines. PMT treatment resulted in TRAP-positive osteoclast 
formation with PMT comparable to stimulation with M-CSF/
sRANKL (Figure 1A; Figure S2 in Supplementary Material). We 
then tested whether the observed osteoclastogenesis in BMDMs 
was due to a direct effect of PMT. As PMT is known to deamidate 
the alpha-subunit of heterotrimeric Gq, we checked the kinetics 
of deamidation of Gq in BMDMs (29). We observed a very rapid 
uptake of the toxin resulting in the deamidation of Gq already after 
1 h of PMT stimulation that persisted for at least 72 h (Figure 1B). 
We next compared the expression of osteoclast markers in 
PMT-treated macrophages along with M-CSF/sRANKL-treated 
macrophages. Real-time qPCR analysis revealed that PMT stimu-
lation in macrophages induced expression of NFATc1 (Nfatc1), 
acid phosphatase 5, tartrate-resistant (Acp5, TRAP), cathepsin 
K (Ctsk), d2 isoform of vacuolar (H+) ATPase (v-ATPase) V0 
domain (Atp6v0d2, ATP6v0d2), osteoclast associated receptor 
(Oscar, OSCAR), calcitonin receptor, and osteoclast stimulatory 
transmembrane protein (Ocstamp, OC-STAMP) (Figure 1C). We 
further checked the activation of transcription factors essential for 
driving osteoclastogenesis and observed an activation of NFATc1, 
c-Jun, and NF-kB after PMT stimulation (Figure 1D). Next, we 
sought to examine whether PMT-induced osteoclasts were able to 
resorb cortical bovine slices. Indeed, PMT-stimulated osteoclasts 
derived from pure macrophages were able to efficiently resorb 
bone matrix (Figures  1E,F). Further characterization revealed 
significant cathepsin K activity in PMT-treated cells, suggesting 
that PMT induces differentiation of macrophages into functional 
osteoclasts (Figure 1G). Together, these observations suggest that 
PMT induces direct differentiation of BMDMs into functional 
osteoclasts.
PMT induces Differentiation of 
Macrophages into Osteoclasts in a 
ranKl-independent Manner
Osteoprotegerin is a soluble secreted protein of the TNF recep-
tor superfamily that is also known as osteoclast inhibitor factor 
(30). Both OPG and RANK are receptors for RANKL. OPG is an 
antagonistic endogenous receptor that inhibits osteoclastogen-
esis. The OPG–RANKL complex counterbalances the effect of 
the RANK–RANKL complex, thus playing an important role in 
maintaining bone homeostasis.
As PMT induces differentiation of macrophages into osteo-
clasts, we wanted to check the effect of OPG on PMT-induced 
osteoclastogenesis. We treated macrophages with OPG along 
with M-CSF/sRANKL or PMT, respectively, and then assessed 
osteoclast formation. Concomitant treatment with OPG com-
pletely abrogated osteoclast formation after M-CSF/sRANKL 
stimulation but failed to show any significant effect on PMT-
mediated osteoclast formation (Figure 2A). To exclude that PMT 
might outcompete OPG at the concentration used (1  nM), we 
gradually decreased PMT concentrations to as low as 0.01 nM, 
but no variation in the number of TRAP-positive osteoclasts was 
found (Figure S3 in Supplementary Material). Furthermore, we 
checked the effect of OPG on PMT-induced signaling pathways 
and transcription factors. In the presence of OPG, PMT was still 
able to activate NFATc1, NF-kB, and c-Jun (Figure 2B). We vali-
dated this observation by checking the expression of osteoclast 
markers induced by PMT in the presence of OPG (Figure 2C). 
OPG treatment of macrophages along with PMT did not alter the 
expression of Nfatc1, Acp5, Oscar, and Ctsk but upregulated the 
expression of Ocstamp and Atp6v0d2 compared to PMT-treated 
macrophages. Next, we checked the bone resorptive potential of 
osteoclasts derived from PMT treated with OPG. Again, we did 
not observe any loss of function of PMT-generated osteoclasts in 
the presence of OPG, suggesting that OPG treatment does not 
interfere with PMT-mediated osteoclastogenesis (Figures 2D,E). 
Together, these data prove that PMT-induced differentiation 
of macrophages into osteoclasts is RANKL-RANK signaling 
independent.
PMT Primes Macrophages for enhanced 
response to ranKl stimulation
As PMT-mediated osteoclast formation was not blocked by the 
RANKL inhibitor OPG, we wanted to see if PMT could influence 
RANKL-mediated signaling pathways. To check if PMT might 
augment the response of macrophages at low concentrations 
of RANKL, we stimulated macrophages with PMT for 1  day, 
then carefully washed the macrophages with culture medium 
and re-stimulated them with a low amount of sRANKL (20 ng) 
in the presence of M-CSF. We observed a marked increase in 
TRAP-positive cells when the cells had been pretreated with PMT 
compared to the treatment with sRANKL/M-CSF or PMT, alone 
(Figure 3A). This resulted in an enhanced number of resorption 
pits (Figures 3B,C). These observations demonstrate that PMT 
increases the responsiveness of the stimulated progenitor cells for 
RANKL-mediated osteoclastogenesis.
We next determined whether PMT modulates the expression 
of RANK in order to increase the responsiveness of RANKL. 
We observed a slight increase in surface expression but not 
gene expression of RANK at 24 h of treatment with PMT com-
pared to M-CSF-treated samples (Figure 3D; Figures S4A,B in 
Supplementary Material). However, we wondered, if there were 
other effects involved in the increased activity of cells pretreated 
with PMT, given the strong effect of the PMT pretreatment on pit 
formation. As we had seen before that PMT is a strong inducer of 
pro-inflammatory genes, we investigated whether these cytokines 
influence the process of differentiation induced by PMT in 
macrophages.
PMT-induced TnF-alpha and il-6 are 
important Modulators of its 
Osteoclastogenic Potential
We have previously shown that PMT is a strong inducer of NF-kB, 
subsequently causing the induction of pro-inflammatory genes 
(18). This inflammatory reaction occurs independently of TLR4 
or the inflammasome through G-protein-mediated RhoA signal-
ing (31). Therefore, we investigated whether pro-inflammatory 
cytokines influence PMT-mediated osteoclast differentiation. 
TNF-α is secreted by various cell types, including macrophages, 
and is one of the most potent osteoclastogenic cytokines pro-
duced during inflammation. It plays an important role in the 
FigUre 1 | continued
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pathogenesis of rheumatoid arthritis and other forms of chronic 
inflammatory osteolysis (32, 33). Therefore, we investigated the 
kinetics of expression and secretion of TNF-α after PMT stimula-
tion in macrophages. We observed that PMT induces the expres-
sion of TNF-α starting after 1 h of stimulation, with a maximum 
induction after 12 h of stimulation (Figure 4A) and continuous 
secretion of TNF-α for at least 72 h (Figure 4B).
We thus questioned, whether blocking of TNF-α signaling by 
addition of etanercept, a TNF-α antibody, affects PMT-induced 
downstream signaling pathways. Addition of etanercept prior 
FigUre 1 | continued 
Pasteurella multocida toxin (PMT) induces differentiation of bone marrow-derived macrophages (bMDMs) into osteoclasts. (a) BMDMs were 
stimulated with standard concentrations of macrophage colony-stimulating factor (M-CSF), M-CSF/sRANKL, and PMT for 6–10 days as described in Section 
“Materials and Methods.” Cells were then fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity and TRAP+ multinucleated cells (MNCs) were 
counted. The indicated SD was obtained from four experiments (mean ± SD; n = 4). Statistical analysis was performed using analysis of variance (ANOVA) followed 
by Bonferroni’s multiple comparison test (***p ≤ 0.0005; **p ≤ 0.005). (b) To investigate the kinetics of PMT-mediated Gαq deamidation, cells were stimulated for the 
indicated time points with 1 nM PMT prior to lysis. As a control, cells were either stimulated with M-CSF or a catalytically inactive mutant of PMT (PMTC1165S, Mt) for 
the longest time point. The immunoblot was probed with an antibody detecting the deamidated form of Gαq (Q209E) or total Gαq (n = 3). (c) Quantitative RT-PCR 
analysis of gene expression of Acp5 (TRAP), Ctsk (cathepsin K), calcitonin receptor (Calcr), Nfatc1, Oscar, Atp6v0d2, and Ocstamp in BMDMs treated either with 
M-CSF, M-CSF/sRANKL, or PMT; the results were normalized to Rps29 expression. Cells were stimulated for 12 h to check the expression of Nfatc1 and Ocstamp; 
for 24 h to check the expression of Oscar; for 48 h to check the expression of Acp5, Ctsk, and Atp6v0d2; and for 72 h to check the expression of Calcr. The data 
are presented as fold change relative to the expression of M-CSF-treated cells at the same time point. The indicated SD was obtained from three or more 
experiments (mean ± SD; n ≥ 3). No significant difference was observed comparing gene expression of PMT-treated samples with M-CSF/sRANKL-treated sample 
using a paired Student’s t-test. (D) Immunoblot of phosphorylated NF-κB (p-NF-κB), phosphorylated c-Jun (p-c-Jun), NFATc1, and histone in nuclear extracts from 
BMDM treated either with PMT or M-CSF (M) for the indicated time points; histone was used as a loading control (n = 3). (e) Representative photographs of 
resorption pits (left panel) and magnified image of a resorption pit (right panel) induced by M-CSF + RANKL or PMT. Resorption pit is marked with circle. (F) The 
diagram represents the pit area that was calculated by deducting the pit area value of M-CSF + RANKL or PMT, respectively, from MCSF-treated wells (n = 4). 
Resorption pit pictures were evaluated in a blinded fashion, and false-positive pits were excluded by marking similar structures in M-CSF-treated samples. No 
significant difference was observed between PMT-treated samples with M-CSF/sRANKL-treated samples using a paired Student’s t-test (ns, not significant). 
(g) Cells were stimulated with M-CSF, M-CSF/sRANKL, and PMT and lysed as described in Section “Materials and Methods.” Cathepsin K activity was analyzed by 
fluorescence detection measured in duplicates (n = 4). Statistical analysis was performed using one-way ANOVA comparing cells stimulated with M-CSF/sRANKL 
and PMT to the M-CSF sample (*p ≤ 0.05).
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to PMT stimulation in macrophages abrogated p-c-Jun and 
decreased NFATc1 and NF-kB levels in nuclear extracts 
(Figure 4C). The number of TRAP-positive cells was significantly 
reduced (approximately 63%) (Figure 4D), and osteoclast-specific 
gene expression was impaired (Figure  4E). Collectively, these 
results suggest that PMT-induced TNF-α production increases 
its osteoclastogenic potential.
In a previous study, we showed that PMT strongly induces 
interleukin-6 expression of immune cells (34). In mice, overex-
pression of IL-6 leads to arthritis while absence of IL-6 prevents 
formation of arthritis in an experimental murine system (35, 
36). In addition, enhanced IL-6 levels are observed in the joints 
and serum of rheumatoid arthritis patients (37). This prompted 
us to check the expression and secretion of IL-6 in BMDM. We 
observed expression of IL-6 after 1 h until 72 h of stimulation with 
PMT (Figure 5A) and the 100-fold increased expression of IL-6 
resulted in an enhanced and sustained IL-6 secretion (Figure 5B). 
These observations suggest that in addition to TNF-α, IL-6 may 
help PMT in driving osteoclastogenesis.
We next evaluated the effect of a murine anti-IL-6R antibody 
(MR-16) on PMT-induced NFATc1, c-Jun, and NF-kB activation. 
Anti-IL-6R antibody treatment reduced PMT-induced activation 
of these transcription factors (Figure 5C) and, as a consequence, 
osteoclast formation (Figure 5D), and expression of osteoclast-
specific genes was reduced (Figure 5E). Together these observa-
tions suggest that PMT-mediated osteoclast formation relies, at 
least in part, on the osteoclastogenic effects of IL-6 and TNF-α.
PMT induces Osteoclastogenesis in 
absence of il-1 receptor
Like IL-6 and TNF-α, IL-1α and IL-1β are important osteoclasto-
genic cytokines (38). Mice deficient in IL-1α, IL-1β, and IL-1α/β 
suppress arthritis in a mouse model, suggesting that both forms 
of IL-1 are required for inflammatory bone loss (39). We observed 
strongly enhanced expression of both, Il1a and Il1b after 12 h of 
PMT treatment that lasted until 72 h (Figures 6A,B). As IL-1α 
and IL-1β transduce signals by binding to IL-1R, we inves-
tigated the effect of PMT on BMDM cells derived from IL-1R 
knockout mice (40). Macrophages deficient in IL-1R showed 
no differences in the activation of NF-kB, p-c-Jun and NFATc1, 
respectively (Figure 6C) and IL-1R-deficient BMDM differenti-
ated into TRAP-positive cells similar to wild-type macrophages 
(Figure 6D). However, when we tested the cells for their ability 
to resorb bone, IL-1R-deficient osteoclasts treated with PMT 
seemed to act slightly less efficient, although the difference did not 
reach statistical significance (Figures  6E,F). Also, we observed 
comparable expression of osteoclast marker genes after PMT 
stimulation in IL-1R knockout macrophages (Figure  6G). In 
summary, these observations suggest that PMT can differentiate 
macrophages into functional osteoclasts in the absence of IL-1R.
cytokines are necessary but not 
sufficient for PMT-induced 
Osteoclastogenesis
While it is generally accepted that RANKL is necessary to induce 
the differentiation of osteoclasts from precursor cells, some 
publications raise the question whether RANKL-independent 
osteoclastogenesis can occur under physiological or pathologi-
cal conditions. It was described that sustained stimulation with 
cytokines allows osteoclast formation (41, 42). Therefore, we 
investigated whether the induction of cytokines by PMT is suf-
ficient to induce OC formation. BMDM were treated with the 
amount of IL-6, TNF-α, and IL-1β that had been measured in 
the ELISA experiments. Quantification of TRAP-positive cells 
showed that the addition of cytokines alone did not induce 
osteoclast formation, neither in the presence nor absence of a 
supporting M-CSF stimulus (Figure  7A). In addition, we did 
not observe any synergistic effect of those cytokines on M-CSF/
FigUre 2 | continued
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FigUre 2 | continued 
Pasteurella multocida toxin (PMT)-mediated osteoclastogenesis is unaltered with osteoprotegerin (OPg) treatment. (a) Bone marrow-derived 
macrophages (BMDMs) were stimulated either with PMT, PMT/OPG, M-CSF/sRANKL, M-CSF/sRANKL/OPG, or macrophage colony-stimulating factor (M-CSF) 
alone for 6–10 days (PMT 1 nM; OPG 100 ng/ml; M-CSF 25 ng/ml; sRANKL 100 ng/ml). Multinucleated TRAP+ cells were counted per well. The indicated SD was 
obtained from two or more experiments measured in duplicates (mean ± SD; n ≥ 2). Statistical analysis was performed using ANOVA followed by Bonferroni’s 
multiple comparison test (***p ≤ 0.0005; NS, not significant). (b) BMDMs were treated with M-CSF, PMT, or with PMT/OPG for 24 h, and nuclear extracts were 
prepared. The immunoblot shows phosphorylated NF-κB (p-NF-κB), phosphorylated c-Jun (p-c-Jun), NFATc1, and histone, which was used as a loading control 
(n = 2). (c) Quantitative RT-PCR analysis of gene expression of Acp5, Ctsk, Ocstamp, Nfatc1, Oscar, and Atp6v0d2 in BMDMs treated either with M-CSF, PMT/
OPG, or PMT; values were normalized to Rps29 expression. Data are presented fold change relative to the gene expression of M-CSF-treated cells at the same time 
point. Cells were stimulated for 12 h to check the expression of Nfatc1 and Ocstamp; for 24 h to check the expression of Oscar; and for 48 h to check the 
expression of Acp5, Ctsk, and Atp6v0d2. The indicated SD was obtained from three or more experiments (mean ± SD; n ≥ 3). Statistical analysis was performed 
using a paired Student’s t-test comparing gene expression of PMT/OPG-treated cells to the PMT-treated cells (*p ≤ 0.05). (D) Representative picture of bone 
resorption assays performed with PMT-stimulated cells with or without OPG. Resorption pits are marked with circles. (e) The histogram represents the calculated pit 
area that was obtained by subtracting the pit area value of PMT or PMT/OPG wells from M-CSF-treated conditions (n ≥ 3). The resorption pit pictures were 
evaluated in a blinded fashion and the false-positive pits were excluded by marking similar structures in M-CSF-treated samples. Statistical analysis was performed 
using a paired Student’s t-test comparing PMT + OPG treatment with PMT-treated sample (NS, not significant).
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sRANKL-treated cells. To verify that the cytokine amounts used 
were appropriate, we checked the activity of specific transcription 
factors (Figure 7B). Although there was a strong cytokine-specific 
activation of STAT-3 and NF-κB comparable to that induced by 
PMT, this activity was insufficient to induce osteoclast formation.
We next studied the effect of an inhibition of all three 
osteoclastogenic cytokines investigated in osteoclast formation 
(Figure  7C). Simultaneous inhibition of IL-6 and TNF-α sub-
stantially decreased osteoclast formation by 72% for both WT and 
IL-1R-deficient mice compared to 63% for etanercept alone and 
49% for IL-6R inhibition. These data imply that while cytokines 
are needed to successfully induce PMT-mediated osteoclast for-
mation, the presence of cytokines alone is not sufficient and that 
other G-protein-related signaling pathways are required.
DiscUssiOn
Pasteurella multocida toxin is a bacterial protein toxin that is 
known to manipulate host cell signaling cascades which for many 
cell types result in the activation of mitogenic pathways and the 
production of cytokines (17). In AR PMT signaling influences 
bone degeneration by accelerating osteoclast formation and by 
inhibiting osteoblast differentiation and function. In this study, we 
show that PMT stimulation of macrophages leads to the induc-
tion of osteoclast markers similar to M-CSF/sRANKL stimulation 
resulting in the differentiation of macrophages into functional 
osteoclasts. Additionally, we show that PMT-derived osteoclasts 
are able to resorb bone similar to classical osteoclasts derived from 
M-CSF/sRANKL stimulation. Strack et al. have recently discussed 
that PMT-induced differentiation of monocytes into osteoclasts 
might be RANKL-independent, however, they did not show any 
experimental proof of their speculation (27). Our data show for 
the first time that PMT-induced osteoclast formation does not 
depend on RANKL-RANK signaling. OPG treatment with PMT 
did not alter the activation of essential transcription factors or the 
expression of osteoclast marker genes, and the resulting osteoclasts 
were able to resorb bone without any loss of function.
Additionally, we show for the first time that the PMT-induced 
inflammatory cytokines such as TNF-α, IL-6, and IL-1 play a 
central role in mediating differentiation of macrophages into 
osteoclasts. TNF-α alone is a weak inducer of osteoclastogenesis 
in mouse BMDM (43), but has been reported to induce functional 
osteoclast formation along with IL-6 (44) or IL-1 (45). Recently, 
Yarilina et  al. have shown that prolonged TNF-α exposure of 
human macrophages can trigger differentiation of macrophages 
into osteoclasts (46). We also observe a sustained production of 
TNF-α after PMT stimulation in macrophages, and this continu-
ous exposure of macrophages to TNF-α may additionally help 
PMT in inducing osteoclastogenesis. In accordance, our in vitro 
study using etanercept strongly reduced PMT-induced osteoclast 
formation (Figures 4C–E), suggesting that TNF-α plays a crucial 
role in PMT-mediated osteoclastogenesis. PMT stimulation also 
caused the continuous increased production of IL-6. In rheuma-
toid arthritis, overproduction of IL-6 is observed and there is a 
correlation between elevated IL-6 level and clinical indices (47, 
48). When we blocked IL-6 signaling, a decrease in PMT-induced 
osteoclast formation in macrophages was observed (Figures 5C–
E). A similar observation was made by Axmann et al. where IL-6R 
blockade directly suppressed M-CSF/RANKL-induced osteoclast 
formation (49).
Similar to TNF-α and IL-6, we observed a high expression of 
IL-1α and β after PMT stimulation of macrophages. However, 
our observations in IL-1R knockout mice suggest that PMT can 
induce differentiation of macrophages into functional osteoclast 
even in the absence of IL-1R signaling, suggesting that IL-1α 
and IL-1β do not directly contribute to PMT-induced osteoclast 
formation in macrophages. However, under physiological condi-
tions, where other IL-1R expressing cells are available, PMT-
induced IL-1 production from macrophages may contribute in 
the progression of AR by either inhibiting osteoblast-mediated 
bone formation (50) or by inducing the expression of factors sup-
porting osteoclastogenesis such as prostaglandin E2 or RANKL 
by osteoblasts/stromal cells (51, 52).
The current literature suggests that under physiological 
conditions the RANKL/RANK axis drives functional osteoclast 
formation. Pathological conditions, such as cancer or auto-
inflammatory bone diseases, are characterized by the presence of 
a specific microenvironment, where the increased expression of 
inflammatory cytokines can provide an additional stimulus that 
further potentiates the generation of bone-resorbing osteoclasts 
(42, 53). Our data also suggest that the PMT-mediated effect 
on osteoclasts is probably due to two signaling cascades. While 
FigUre 3 | Pasteurella multocida toxin (PMT) pre-treatment augments M-csF/ranKl-induced osteoclastogenesis in macrophages. (a) Bone 
marrow-derived macrophages were treated with stimuli as indicated for 10 days using high (100 ng/ml) and low (20 ng/ml) concentrations of RANKL. TRAP+ 
multinucleated cells (MNCs) were counted (mean ± SD; n = 2). Statistical analysis was performed using analysis of variance (ANOVA) followed by Bonferroni’s 
multiple comparison test comparing TRAP+ cells treated with PMT for 1 day before switching to low M-CSF/sRANKL concentrations with samples treated only with 
PMT, M-CSF/sRANKL (high), or M-CSF/sRANKL (low), respectively (***p ≤ 0.0005). (b) Graph of the calculated pit area that was obtained by deducting the pit area 
value of macrophage colony-stimulating factor (M-CSF)-treated conditions from the respective samples (mean ± SD; n = 3). Resorption pit pictures were evaluated 
in a blinded fashion, and false-positive pits were excluded by marking similar structures in M-CSF-treated samples. Statistical analysis was performed using ANOVA 
followed by Bonferroni’s multiple comparison test comparing pit areas in samples treated with PMT for 1 day before switching to M-CSF/sRANKL (low) with PMT, 
M-CSF/sRANKL (high), or M-CSF/sRANKL (low) samples (**p ≤ 0.005; ***p ≤ 0.0005). (c) Representative photographs of resorption pits (left panel) and magnified 
image of a resorption pit (right panel). Resorption pit is marked with circle. (D) FACS analysis of RANK surface expression after 1 day of treatment with M-CSF/
sRANKL or PMT (mean ± SD; n = 3). Statistical analysis of RANK expression was performed using ANOVA followed by Bonferroni’s multiple comparison test 
(*p ≤ 0.05).
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FigUre 4 | TnF-α modulates Pasteurella multocida toxin (PMT)-induced osteoclastogenesis. (a,b) Bone marrow-derived macrophages (BMDMs) were 
stimulated with standard concentration of macrophage colony-stimulating factor (M-CSF), M-CSF/sRANKL, or PMT for the indicated the time points. 
(a) Quantitative RT-PCR analysis of Tnf normalized to Rps29 expression. Data are presented fold change relative to the expression of M-CSF-treated cells at the 
same time point (mean ± SD; n = 3). (b) ELISA of TNF-α production (mean ± SD; n = 3). Statistical analysis was done by two-way analysis of variance (ANOVA) 
(***p ≤ 0.001). (c) BMDMs were stimulated with PMT, PMT/etanercept (120 µg/ml) or M-CSF for 24 h, and nuclear extracts were prepared. Immunoblots of nuclear 
phosphorylated NF-κB (p-NF-κB), c-Jun (p-c-Jun), NFATc1, and histone were performed (n = 2). (D) BMDMs were stimulated with PMT, PMT/etanercept (120 µg/
ml), or M-CSF for 10 days. Multinucleated TRAP+ cells were counted per well. The indicated SD was obtained from four experiments (mean ± SD; n = 4). Statistical 
analysis was performed using ANOVA followed by Bonferroni’s multiple comparison test comparing TRAP+ cells in PMT/etanercept-treated wells to the PMT- and 
M-CSF-treated wells; TRAP+ cells in PMT-treated wells to the M-CSF-treated wells (***p ≤ 0.0005). (e) Quantitative RT-PCR analysis of gene expression of Acp5, 
Oscar, Atp6v0d2, and Ocstamp in BMDMs treated either with PMT, PMT/etanercept, or M-CSF; data were normalized to Rps29 expression. Cells were stimulated 
for 12 h to check the expression of Ocstamp; for 24 h to check the expression of Oscar; and for 48 h to check the expression of Acp5 and Atp6v0d2. The data are 
presented as fold change relative to the expression of M-CSF-treated cells at the same time point. The indicated SD was obtained from three or more experiments 
(mean ± SD; n ≥ 3). Statistical analysis was performed using a paired Student’s t-test comparing gene expression of PMT/etanercept-treated cells to the 
PMT-treated cells (*p ≤ 0.05; **p ≤ 0.005).
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FigUre 5 | Pasteurella multocida toxin (PMT)-mediated osteoclastogenesis is inhibited with blockade of interleukin 6 receptor (il-6r). (a,b) Bone 
marrow-derived macrophages (BMDMs) were stimulated with standard concentrations of macrophage colony-stimulating factor (M-CSF), M-CSF/sRANKL, or PMT 
for the indicated time points. (a) Quantitative RT-PCR analysis of Il6 mRNA; normalized to Rps29 expression. Data are presented fold change relative to the 
expression of M-CSF-treated cells at the same time point (mean ± SD; n = 3). (b) ELISA of IL-6 production (mean ± SD; n = 3). Statistical analysis was done by 
analysis of variance (ANOVA) (***p ≤ 0.001). (c) BMDMs were stimulated with PMT, PMT/anti IL-6 R (105 µg/ml), or M-CSF for 24 h, and nuclear extracts were 
prepared. A representative immunoblot of the phosphorylated forms of NF-κB (p-NF-κB) and c-Jun (p-c-Jun), as well as NFATc1 and histone are shown; histone 
was used as a loading control (n = 2). (D) BMDMs were stimulated with PMT, PMT/Anti IL-6R (105 µg/ml), or M-CSF for 10 days. Multinucleated TRAP+ cells were 
counted per well. The indicated SD was obtained from three experiments (mean ± SD; n ≥ 3). Statistical analysis was performed using ANOVA followed by 
Bonferroni’s multiple comparison test comparing TRAP+ cells in PMT/Anti IL-6R-treated wells to the PMT- and M-CSF-treated wells; TRAP+ cells in PMT-treated 
wells to the M-CSF-treated wells (***p ≤ 0.0005). Statistical analysis was performed using a paired Student’s t-test comparing (***p ≤ 0.0005). (e) Quantitative 
RT-PCR analysis of gene expression of Acp5, Oscar, Atp6v0d2, and Ocstamp in BMDMs treated either with PMT, PMT/Anti-IL6 R (105 µg/ml), or M-CSF alone; 
values were normalized to Rps29 expression (mean ± SD; n = 3). Cells were stimulated for 12 h to check the expression of Ocstamp; for 24 h to check the 
expression of Oscar; and for 48 h to check the expression of Acp5 and Atp6v0d2. The data are presented as fold change relative to the expression of M-CSF-
treated cells at the same time point. Statistical analysis was performed using a paired Student’s t-test comparing gene expression of PMT/Anti IL-6R-treated cells 
with PMT-treated cells (*p ≤ 0.05).
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FigUre 6 | continued
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FigUre 7 | cytokines alone are not sufficient to mimic Pasteurella 
multocida toxin (PMT)-stimulated osteoclast differentiation. (a) Bone 
marrow-derived macrophages (BMDMs) were stimulated with macrophage 
colony-stimulating factor (M-CSF) or M-CSF/sRANKL with or without addition 
of cytokines: TNF-α (700 pg/ml), IL-6 (2,500 pg/ml), and IL-1β (900 pg/ml) 
and PMT alone for 10–12 days and multinucleated TRAP+ cells were 
counted. The indicated SD was obtained from three experiments 
(mean ± SD). Statistical analysis was performed using one-way analysis of 
variance (ANOVA) comparing the difference of tartrate-resistant acid 
phosphatase (TRAP)-positive cells derived from PMT or cytokine treatment 
compared to M-CSF/sRANKL-treated control cells. (b) BMDMs were 
stimulated with PMT, M-CSF, or M-CSF with cytokines (a) for 1½ days. Total 
lysates were prepared and immunoblots for phosphorylated STAT-3 
(p-STAT-3), phosphorylated NF-κB (p-NF-κB), and β-actin were performed 
(n = 3). (c) BMDMs from wt and IL-1R-deficient mice were stimulated with 
PMT, M-CSF, or PMT in combination with etanercept (120 µg/ml) and the 
IL-6 neutralizing antibody (105 µg/ml) for 10–12 days. Multinucleated TRAP+ 
cells were quantified and the indicated SD was obtained from three 
experiments (mean ± SD; n = 3). Statistical analysis was performed using 
one-way ANOVA comparing the decrease of TRAP-positive cells in 
inhibitor-treated versus PMT-treated control cells.
FigUre 6 | continued 
absence of interleukin 1 receptor (il-1r) fails to block Pasteurella multocida toxin (PMT)-induced osteoclast formation. (a,b) Bone marrow-derived 
macrophages (BMDMs) were stimulated as described using standard concentrations of macrophage colony-stimulating factor (M-CSF), M-CSF/sRANKL, or PMT 
for the indicated time points. Graphs show quantitative RT-PCR analysis of Il1a and Il1b mRNA levels normalized to Rps29 expression. The data are presented as 
fold change relative to the expression of M-CSF-treated cells at the same time point (mean ± SD; n ≥ 2). Statistical analysis was done by two-way ANOVA 
(***p ≤ 0.001). (c) BMDMs from wt and IL-1R-deficient mice were stimulated with PMT or M-CSF for 24 h before nuclear extracts were prepared. Immunoblots of 
phosphorylated NF-κB (p-NF-κB), c-Jun (p-c-Jun), NFATc1, and histone were performed. Histone served as a loading control (n = 4). (D) BMDMs from wt and 
IL-1R-deficient mice were stimulated with PMT and M-CSF for 10 days. Multinucleated TRAP+ cells were counted; the indicated SD was obtained from four 
experiments (mean ± SD; n ≥ 3). Statistical analysis was performed using a paired Student’s t-test comparing TRAP+ cells in PMT-treated wells to the M-CSF-
treated wells (**p ≤ 0.005; ***p ≤ 0.0005). (e) Representative pictures of bone resorption assays using osteoclasts from wt and IL-1R-deficient mice are shown. 
Resorption pits are marked with a circle. (F) Bone resorption assay of BMDMs derived from wt and IL-1R-deficient mice and differentiated into osteoclasts with PMT. 
The data presented show the pit area that was calculated by subtracting the pit area value of the M-CSF from the PMT-treated condition (n = 6). The resorption pit 
pictures were evaluated in a blinded fashion and false-positive pits were excluded by marking similar structures in M-CSF-treated samples. (g) Quantitative RT-PCR 
analysis of gene expression of Acp5, Oscar, Nfatc1, and Ctsk in BMDMs derived from wild-type mice or IL-1R-deficient mice, treated with M-CSF or PMT, 
normalized to Rps29 expression. Cells were stimulated for 12 h to check the expression of Nfatc1; for 24 h to check the expression of Oscar; and for 48 h to check 
the expression of Acp5 and Ctsk. The data are presented as fold change relative to the expression of M-CSF-treated cells at the same time point. The indicated SD 
was obtained from four experiments (mean ± SD; n = 4). Statistical analysis was performed using unpaired Student’s t-test comparing gene expression to the 
M-CSF-treated samples (*p ≤ 0.05; **p ≤ 0.005; ***p ≤ 0.0005).
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PMT-induced cytokine production seems to be necessary to 
allow efficient osteoclast formation, additional PMT-mediated 
signaling is required. Strack et al. recently showed that NFATc1 is 
activated by PMT downstream of the activated Gαq subunit (27). 
In addition, NFATc1 overexpression is known to be sufficient 
for the induction of osteoclastic genes, even in the absence of 
RANKL (54). Interestingly, NFATc1 expression was not effectively 
reduced in our inhibitor experiments, and thus, we hypothesize 
that Gq-dependent expression of NFATc1 could be the additional 
signal needed for osteoclast formation. This would also explain 
why inhibition of cytokines did not abrogate osteoclast formation 
completely, as there is still a robust Gq-mediated induction of 
NFATc1 transcriptional activity even in the absence of IL-6 and 
TNF-α signaling. Collectively, our data suggest that PMT-induced 
osteoclastogenesis is dependent on cytokines and Gq-mediated 
signaling but independent of RANKL/RANK axis. A recent 
article speculates about the possibility of osteoclast subtypes 
based on large number of studies showing the existence of vari-
ous subsets of myeloid cells under physiological or pathological 
state (55). Therefore, we suggest that osteoclasts generated with 
PMT are distinct from RANKL-derived osteoclasts and are likely 
to represent a separate subset of osteoclasts; however, detailed 
future investigations are required for validating our assumption.
Although GPCR signaling is recognized as an important 
player for many human pathologies, including cardiovascular 
diseases, inflammation, and cancer, the importance of G proteins 
in auto-inflammatory bone diseases has not been addressed yet. 
We recently showed that PMT triggers the differentiation of naïve 
T cells into a osteoclastogenesis-promoting Th17 phenotype as a 
consequence of constitutive Gq activation and the resulting down-
stream activation of STAT-3 (56, 57). This seems to be in contrast 
with findings of Liu et al. who report that a lack of Gq triggers 
Th17 differentiation in human lymphocytes (58, 59). However, 
their data compared mRNA levels but not cellular Gq activity, 
which for GTPases is a more relevant readout. In support of our 
findings, other scientists suggest that activation of G proteins by 
AlF4 treatment activates osteoclast differentiation (60) and that 
elevated expression of Gq in osteoblasts increases osteoclastogen-
esis in a transgenic mouse model (61). New therapeutic tools to 
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inhibit G protein signaling are currently being characterized, and 
it remains to be seen whether they will provide helpful tools in the 
treatment of auto-inflammatory diseases such as RA as well (62).
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